LIMK2 and neoplasm: LIMK1 was reported to be overexpressed in colorectal cancer tissues and functioned as a competitive inhibitor of LIMK2 to promote the nuclear translocation of β-catenin, thus promoting tumor progression through activation of the Wnt/β-catenin pathway [24].